22 March, 2021
Oral coronavirus vaccine will soon begin clinical trials in the near future after its developers reported promising preliminary data.
The oral Covid-19 drug, called Oravax, is being developed by Israeli-American Oramed Pharmaceuticals and India-based Premas Biotech. The two companies have teamed up to create Oravax Medical Inc.
A pilot study conducted on animals discivered that the oral vaccine helped produce antibodies that create immunity against the virus according to the company claims. This outcomes were achieved administering a single Oravax capsule, potentially setting the drug apart from some of the other vaccines which require two doses.
The co-founder of Premas Biotech, Prabuddha Kundu, told Indian media that administering the vaccine would be “like taking a vitamin pill” and that “we are more than 100% sure that the technology works and is promising.” He also informed that the results from the preliminary animal tests would soon be published in a scientific journal.
Acoording to Oramed CEO Nadav Kidron, the oral drug would eliminate logistical problems that have arisen from worldwide mass vaccination drives, and that the pill could even be taken by individuals from the comfort of their home.
He also told the told the Jerusalem Post that the drug can be moved at refrigerator temperature and even stored at room temperature, alleviating some of the issues with some traditional vaccines, which must be kept extremely cold before use. Kidron further claimed that administering the vaccine orally could result in fewer side effects.
The capsules would become particularly useful if Covid-19 vaccines are eventually “recommended annually like the standard flu shot,” he said.
Oravax Medical is currently applying to conduct human trials in Isreal,United States, Europe and Mexico, and Europe.